Benefits documented in studies fade significantly by 4-6 months post-treatment regardless of initial response
GLP-1based therapy may not be appropriate if you have: -History of medullary thyroid cancer -History of gallbladder disease -History of pancreatitis -Multiple endocrine neoplasia syndrome type 2 (MEN2)
In research contexts, subcutaneous GHK-Cu injection is being explored for its systemic effects particularly its potential to deliver anti-inflammatory, tissue-regenerative, and gene-expression-modulating effects to tissues beyond the skin, including muscles, joints, internal organs, and the central nervous system
There is no public list from the Indonesian government of exactly which prescription drugs are considered controlled or contraband (Indonesia International Travel Information), so its best to err on the side of caution: assume anything that affects the nervous system (painkillers, sedatives, stimulants) is scrutinized
Supplementary tables: Table S1
